SCHEMBL359673

SCHEMBL359673

CNC(=O)C[C@H](N)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.50
GRIK1 P39086 9/20 0.48
GRIK2 Q13002 5/20 0.48
GRM1 Q13255 1/20 0.46
GRM2 Q14416 1/20 0.46
SLC1A3 P43003 6/20 0.46
SLC1A2 P43004 6/20 0.46
SLC1A1 P43005 5/20 0.46
GRIA4 P48058 3/20 0.45
GRIK3 Q13003 3/20 0.45
GRIK5 Q16478 3/20 0.45
GRIA2 P42262 2/20 0.44
GRIA1 P42261 1/20 0.44
PTGS1 P23219 1/20 0.42
SLC7A11 Q9UPY5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8368782 1.00 SLC7A5 (0.50) SLC7A5GRIK1GRIK2GRM1GRM2
SCHEMBL515168 1.00 SLC7A5 (0.50) SLC7A5GRIK1GRIK2GRM1GRM2
Glutamine SCHEMBL3192030 0.85 ALOX15 (0.66) SLC7A5GRIK1GRIK2GRM1GRM2
Glutamine SCHEMBL3192024 0.85 ALOX15 (0.66) SLC7A5GRIK1GRIK2GRM1GRM2
SCHEMBL9949059 0.82 SLC7A5 (0.44) SLC7A5GRIK1GRIK2GRM1GRM2
SCHEMBL12534395 0.81 SLC1A3 (0.35) GRIK1GRIK2SLC1A3SLC1A2SLC1A1
SCHEMBL21896210 0.81 MCL1 (0.34) SLC7A5GRIK1GRIK2SLC1A3SLC1A2
SCHEMBL16280988 0.81 SLC1A3 (0.35) GRIK1GRIK2SLC1A3SLC1A2SLC1A1
SCHEMBL15145068 0.81 MCL1 (0.34) SLC7A5GRIK1GRIK2SLC1A3SLC1A2
SCHEMBL13329918 0.80 SLC7A5 (0.41) SLC7A5GRIK1GRIK2SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025149851-A2 METHODS FOR TREATING INFLAMMATORY DISEASES YUYU PHARMA, INC. (KR) 2025-07-17 WO claimed
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 WO claimed
US-20240301023-A1 PEPTIDES AND USES THEREOF PreveCeutical Medical Inc. (CA) 2024-09-12 US claimed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US claimed
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU PHARMA, INC. (KR) 2023-05-11 US claimed
EP-4175970-A1 PEPTIDES AND USES THEREOF Preveceutical Medical Inc. (CA) 2023-05-10 EP claimed
EP-4114430-A2 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS YUYU Pharma, Inc. (KR) 2023-01-11 EP claimed
WO-2022000043-A1 PEPTIDES AND USES THEREOF PreveCeutical Medical Inc. (CA) 2022-01-06 WO claimed
WO-2019179985-A1 INHIBITORS OF MINT AND USES THEREOF UNIVERSITY OF COPENHAGEN (DK) 2019-09-26 WO claimed
US-9101662-B2 Compositions with modulating agents FOAMIX PHARMACEUTICALS LTD. (IL) 2015-08-11 US claimed
US-8795693-B2 Compositions with modulating agents FOAMIX LTD. (IL) 2014-08-05 US claimed
EP-2097065-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS Foamix Ltd. (IL) 2009-09-09 EP claimed
WO-2008152444-A2 FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS FOAMIX LTD. (US) 2008-12-18 WO claimed
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions FOAMIX LTD. (IL) 2008-08-28 US claimed
WO-2004021981-A2 METHODS FOR THE PREPARATION OF β-AMINO ACIDS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2004-03-18 WO claimed
US-20030113882-A1 Methods for the preparation of beta-amino acids WISCONSIN ALUMNI RESEARCH FOUNDATION 2003-06-19 US claimed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 EP disclosed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 EP disclosed
EP-0528312-A2 Cyclic peptides and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1993-02-24 EP disclosed
EP-0308983-A2 NMR imaging with Mn(II) coordination compositions SALUTAR, INC. (US) 1989-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240301023-A1 PEPTIDES AND USES THEREOF OPRL1, OPRK1, OPRM1 SLC7A5 2757/4885GRIK1 1069/4885GRIK2 1269/4885
US-20080206159-A1 Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions CUTA, SLTM, SMO SLC7A5 4410/4885GRIK1 2104/4885GRIK2 2050/4885
US-20230146455-A1 TREATMENT OF INFLAMMATORY DISEASES WITH PEPTIDES AND PHARMACEUTICAL COMPOSITIONS VIP, TSLP, IAPP SLC7A5 4219/4885GRIK1 1771/4885GRIK2 1990/4885
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient VIP, IAPP, NGLY1 SLC7A5 2363/4885GRIK1 2190/4885GRIK2 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.